Vibe coder here @claudeaiwatch Fed up with "you're absolutely right" energy, I built a museum for it. ClaudeWatch is live: claudewatch.org Independent archive of Claude failure modes, capacity theater, quality dips, and harness drama. We file public posts from @claudeai and @ClaudeDevs (plus pattern cases), then add a thin coat of satire so the corporate calm does not sandblast the stakes. Not affiliated with Anthropic. We just keep the footnotes. Timeline → claudewatch.org/timeline/ Cases → claudewatch.org/cases/ Tips → [email protected]

Seven. That is how many new molecules discovered in India by Indian drugmakers have been approved since 2013, by a count from company and regulator records. On 27 October, a Supreme Court judge asked the government's lawyer to name five such molecules in 30 years. LiveLaw reported the lawyer was not familiar enough with the subject to answer. The court then reserved its order. So why can't the new price cap explain the short list? India's drug price regulator, not the court, capped the markup between a maker's price to distributors and the printed price on cancer drugs. The maker's price stays free. None of the seven molecules is a covered drug, and all were approved before the order. Whatever has kept India's list of new medicines short, it was at work long before this cap.

Fact from fiction: There is absolute no embargo on the price a company can charge by regulator and courts. It is price which retailer and hospitals charge is challenged. Seven. That is how many new molecules discovered in India by Indian drugmakers have been approved since 2013, by a count from company and regulator records. On 27 October, a Supreme Court judge asked the government's lawyer to name five such molecules in 30 years. LiveLaw reported the lawyer was not familiar enough with the subject to answer. The court then reserved its order. A venture capital investor argues on X that court pressure on drug prices explains why Indian drugmakers invest little in research. The post warns India will soon depend on China for medicines. So why can't the new price cap explain the short list? India's drug price regulator, not the court, capped the markup between a maker's price to distributors and the printed price on cancer drugs. The maker's price stays free. None of the seven molecules is a covered drug, and all were approved before the order. Whatever has kept India's list of new medicines short, it was at work long before this cap.

Debunking fact from fiction: Seven. That is how many new molecules discovered in India by Indian drugmakers have been approved since 2013, by a count from company and regulator records. On 27 October, a Supreme Court judge asked the government's lawyer to name five such molecules in 30 years. LiveLaw reported the lawyer was not familiar enough with the subject to answer. The court then reserved its order. A venture capital investor argues on X that court pressure on drug prices explains why Indian drugmakers invest little in research. The post warns India will soon depend on China for medicines. So why can't the new price cap explain the short list? India's drug price regulator, not the court, capped the markup between a maker's price to distributors and the printed price on cancer drugs. The maker's price stays free. None of the seven molecules is a covered drug, and all were approved before the order. Whatever has kept India's list of new medicines short, it was at work long before this cap. @malpani @malini_aisola @RemaNagarajan @anupsoans @drbabukv

₹29,600. In 2017, that became the ceiling price for a drug-eluting stent, a mesh tube that holds open a blocked heart artery. Within months, the head of India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), wrote that "several hospitals have increased the various 'procedure charges' in order to compensate for their losses." A Mumbai surgeon warns hospitals may respond alike to NPPA's 30% cap on trade margins for cancer drugs. A trade margin is the gap between a maker's price to distributors and the printed price. With stents, the surgeon wrote, procedure charges rose "to keep package cost the same." A child psychiatrist called the surgeon "spot on." So did hospitals keep the stent bill whole? The record is mixed. Months later, insurers told The Indian Express angioplasty claims had not fallen to match. One Mumbai hospital's records showed costs falling for single-room patients. The stent cap reached one line on the bill. The cancer order reaches the drug lines, and is silent on the rest. Follow overcharged.in to see how much you are overcharged by hospitals city wise

₹80,071.86. That was the printed price of one 100 mg vial of Samtepa, a brand of the chemotherapy injection thiotepa. Its maker has reported a new price of ₹7,150.33 from 9 November. The figures come from India's drug price regulator, the NPPA. The maximum retail price, or MRP, is the most a shop or hospital can charge. A Mint health reporter shared the cut, describing thiotepa as an injection "to treat bladder cancer." Mint's story adds its use before stem cell transplants. Four 100 mg thiotepa brands appear on the regulator's revised list. Samtepa had the highest old price. Now it has the lowest. So why did the ranking flip? The regulator's order caps trade margins, the share kept by distributors and shops, at 30%. Each company resets its MRP from what it charged distributors this year. A brand printed far above its selling price falls furthest. A printed price only told patients the most they could be billed. The new ceiling starts from what the maker actually charged. I made a website which helps pvt citizens to benchmark the hospital costs overcharged.in

₹300. That is the government's rate for a complete blood count at an accredited hospital in a top-tier city. In a smaller, lower-tier city, the same test is ₹240. I built overcharged.in to search those rates. It holds the CGHS schedule, the central government health scheme's price list, across 2,594 procedure entries. One procedure has many rates. City tier changes it. So does NABH accreditation, the national hospital quality standard, and the patient's ward. The site reads the published value for each combination. Hospital prices are meant to come from hospitals. Rules from 2012 require hospitals, where the law applies, to display their rates for each service. This month, the Union Health Secretary asked states to enforce them. A search box can hold the government's price. Only the hospital can post its own.

₹80,071.86. That was the printed price of one 100 mg vial of Samtepa, a brand of the chemotherapy injection thiotepa. Its maker has reported a new price of ₹7,150.33 from 9 November. The figures come from India's drug price regulator, the NPPA. The maximum retail price, or MRP, is the most a shop or hospital can charge. A Mint health reporter shared the cut, describing thiotepa as an injection "to treat bladder cancer." Mint's story adds its use before stem cell transplants. Four 100 mg thiotepa brands appear on the regulator's revised list. Samtepa had the highest old price. Now it has the lowest. So why did the ranking flip? The regulator's order caps trade margins, the share kept by distributors and shops, at 30%. Each company resets its MRP from what it charged distributors this year. A brand printed far above its selling price falls furthest. A printed price only told patients the most they could be billed. The new ceiling starts from what the maker actually charged. Follow overcharged.in to know how much you pay above the CGHS rates city wise and question the hospitals

I made this in March as a side project this year to help the veterans as ECHS follow CGHS rates. Never new it will so many people . Have added music 🎶 from golmaal movie in case someone is overcharged 🌐 overcharged.in @malpani

₹300. That is the government's rate for a complete blood count at an accredited hospital in a top-tier city. In a smaller, lower-tier city, the same test is ₹240. I built overcharged.in to search those rates. It holds the CGHS schedule, the central government health scheme's price list, across 2,594 procedure entries. One procedure has many rates. City tier changes it. So does NABH accreditation, the national hospital quality standard, and the patient's ward. The site reads the published value for each combination. Hospital prices are meant to come from hospitals. Rules from 2012 require hospitals, where the law applies, to display their rates for each service. This month, the Union Health Secretary asked states to enforce them. A search box can hold the government's price. Only the hospital can post its own.

₹300. That is the government's rate for a complete blood count at an accredited hospital in a top-tier city. In a smaller, lower-tier city, the same test is ₹240. I built overcharged.in to search those rates. It holds the CGHS schedule, the central government health scheme's price list, across 2,594 procedure entries. One procedure has many rates. City tier changes it. So does NABH accreditation, the national hospital quality standard, and the patient's ward. The site reads the published value for each combination. Hospital prices are meant to come from hospitals. Rules from 2012 require hospitals, where the law applies, to display their rates for each service. This month, the Union Health Secretary asked states to enforce them. A search box can hold the government's price. Only the hospital can post its own. @RemaNagarajan @malpani @law_ninja @anupsoans @ramavenu

2,584 procedures. That is how many government rates overcharged.in puts in one search box. I built it. A Mumbai IVF specialist and angel investor shared it as a tool to "protect patients from being exploited by greedy hospitals." The tool claims less. It shows the CGHS rate, the central government health scheme's price list, beside what a patient paid. The gap is arithmetic, not proof of overcharging. One reply asked to "see which hospitals in your neighbourhood were relatively at par or deviated". The specialist answered: "We can seed this, and then start crowdsourcing this." Hospital prices are supposed to be public already. Rules from 2012 require hospitals, where the law applies, to display the rates charged for each service at a conspicuous place. This month, the Union Health Secretary asked states to enforce them. The government's rate fits in a search box. Each hospital's own rate is meant to be on its wall.